Thursday, October 15, 2026

WESCO International, Inc. And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

December 16, 2020

WESCO International, Inc. And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. The ONE Group Hospitality, Inc.

56.4% sales growth and 55.19% return on equity

The ONE Group Hospitality, Inc. sales growth this year is expected to be 22.2% and 35.6% for next year.

Year-on-year quarterly revenue growth grew by 79%, now sitting on 149.15M for the twelve trailing months.

The ONE Group Hospitality, Inc.'s sales growth for the next quarter is 56.4%. The company's growth estimates for the ongoing quarter and the next is 50% and 100%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 55.19%.

The ONE Group Hospitality, Inc.'s Stock Top and Bottom Yearly Value

The ONE Group Hospitality, Inc.'s stock is valued at $3.06 at 01:22 EST, way under its 52-week high of $4.68 and way higher than its 52-week low of $0.73.

The ONE Group Hospitality, Inc.'s Moving Average

The ONE Group Hospitality, Inc.'s worth is higher than its 50-day moving average of $2.79 and way above its 200-day moving average of $2.10.

2. Cadence Design Systems, Inc.

13.8% sales growth and 55.55% return on equity

Cadence Design Systems, Inc. sales growth this year is expected to be 13.6% and 6.6% for next year.

Year-on-year quarterly revenue growth grew by 15%, now sitting on 2.52B for the twelve trailing months.

Cadence Design Systems, Inc.'s sales growth for the next quarter is 13.8%. The company's growth estimates for the present quarter and the next is 37% and 18.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 55.55%.

Cadence Design Systems, Inc.'s Stock Top and Bottom Yearly Value

Cadence Design Systems, Inc.'s stock is valued at $118.52 at 01:22 EST, under its 52-week high of $127.50 and way higher than its 52-week low of $51.39.

Cadence Design Systems, Inc.'s Moving Average

Cadence Design Systems, Inc.'s value is above its 50-day moving average of $114.87 and way above its 200-day moving average of $105.83.

3. Northfield Bancorp, Inc.

15.6% sales growth and 4.7% return on equity

Northfield Bancorp, Inc. sales growth this year is anticipated to be 14.5% and 8.7% for next year.

Year-on-year quarterly revenue growth grew by 9.3%, now sitting on 124.17M for the twelve trailing months.

Northfield Bancorp, Inc.'s sales growth for the next quarter is 15.6%. The company's growth estimates for the ongoing quarter and the next is a negative 4.8% and 100%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.7%.

Northfield Bancorp, Inc.'s Stock Top and Bottom Yearly Value

Northfield Bancorp, Inc.'s stock is valued at $11.77 at 01:22 EST, way under its 52-week high of $17.55 and way higher than its 52-week low of $8.72.

Northfield Bancorp, Inc.'s Moving Average

Northfield Bancorp, Inc.'s worth is higher than its 50-day moving average of $11.07 and way higher than its 200-day moving average of $10.42.

4. Qualys, Inc.

12.4% sales growth and 23.23% return on equity

Qualys, Inc. sales growth this year is anticipated to be 12.8% and 12.5% for next year.

Year-on-year quarterly revenue growth grew by 12.6%, now sitting on 352.83M for the twelve trailing months.

Qualys, Inc.'s sales growth for the next quarter is 12.4%. The company's growth estimates for the ongoing quarter and the next is 9.4% and 6.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 23.23%.

Qualys, Inc.'s Stock Top and Bottom Yearly Value

Qualys, Inc.'s stock is valued at $95.05 at 01:22 EST, way below its 52-week high of $125.22 and way higher than its 52-week low of $63.37.

Qualys, Inc.'s Moving Average

Qualys, Inc.'s value is higher than its 50-day moving average of $92.26 and under its 200-day moving average of $102.30.

5. Futu Holdings Limited

149.2% sales growth and 20.42% return on equity

Futu Holdings Limited sales growth this year is expected to be 170.2% and 51.5% for next year.

Year-on-year quarterly revenue growth grew by 281.7%, now sitting on N/A for the twelve trailing months.

Futu Holdings Limited's sales growth for the next quarter is 149.2%. The company's growth estimates for the ongoing quarter and the next is 100% and negative -40%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.42%.

Futu Holdings Limited's Stock Top and Bottom Yearly Value

Futu Holdings Limited's stock is valued at $41.58 at 01:22 EST, way under its 52-week high of $51.10 and way above its 52-week low of $8.16.

Futu Holdings Limited's Moving Average

Futu Holdings Limited's worth is higher than its 50-day moving average of $39.63 and way higher than its 200-day moving average of $31.68.

6. WESCO International, Inc.

103.2% sales growth and 4.91% return on equity

WESCO International, Inc. sales growth this year is expected to be 47% and 37% for next year.

Year-on-year quarterly revenue growth grew by 92.8%, now sitting on 10.3B for the twelve trailing months.

WESCO International, Inc.'s sales growth for the next quarter is 103.2%. The company's growth estimates for the present quarter and the next is 3% and 13.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.91%.

WESCO International, Inc.'s Stock Top and Bottom Yearly Value

WESCO International, Inc.'s stock is valued at $74.46 at 01:22 EST, under its 52-week high of $74.96 and way higher than its 52-week low of $13.52.

WESCO International, Inc.'s Moving Average

WESCO International, Inc.'s value is way above its 50-day moving average of $58.61 and way above its 200-day moving average of $45.95.

7. New York Community Bancorp, Inc.

24% sales growth and 6.29% return on equity

New York Community Bancorp, Inc. sales growth this year is expected to be 14% and 14.9% for next year.

Year-on-year quarterly revenue growth grew by 10.6%, now sitting on 1.05B for the twelve trailing months.

New York Community Bancorp, Inc.'s sales growth for the next quarter is 24%. The company's growth estimates for the ongoing quarter and the next is 30% and 25%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.29%.

New York Community Bancorp, Inc.'s Stock Top and Bottom Yearly Value

New York Community Bancorp, Inc.'s stock is valued at $10.17 at 01:22 EST, way under its 52-week high of $12.10 and way above its 52-week low of $7.72.

New York Community Bancorp, Inc.'s Moving Average

New York Community Bancorp, Inc.'s worth is way above its 50-day moving average of $9.07 and higher than its 200-day moving average of $9.47.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com